Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study.
Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC; Dutch Initiative on Crohn's and Colitis (ICC). Beelen EMJ, et al. Among authors: ponsioen cij. Ann Surg. 2021 Mar 1;273(3):557-563. doi: 10.1097/SLA.0000000000003395. Ann Surg. 2021. PMID: 31188225
Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasia.
van Schaik FD, Mooiweer E, van der Have M, Belderbos TD, Ten Kate FJ, Offerhaus GJ, Schipper ME, Dijkstra G, Pierik M, Stokkers PC, Ponsioen C, de Jong DJ, Hommes DW, van Bodegraven AA, Siersema PD, van Oijen MG, Oldenburg B; Dutch Initiative on Crohn Colitis. van Schaik FD, et al. Inflamm Bowel Dis. 2013 Feb;19(2):342-9. doi: 10.1097/MIB.0b013e318286f771. Inflamm Bowel Dis. 2013. PMID: 23340679
Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Kestens C, et al. Clin Gastroenterol Hepatol. 2013 Jul;11(7):826-31. doi: 10.1016/j.cgh.2013.01.012. Epub 2013 Jan 29. Clin Gastroenterol Hepatol. 2013. PMID: 23376000
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ. Dewint P, et al. Gut. 2014 Feb;63(2):292-9. doi: 10.1136/gutjnl-2013-304488. Epub 2013 Mar 23. Gut. 2014. PMID: 23525574 Clinical Trial.
Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.
Goetgebuer RL, Kreijne JE, Aitken CA, Dijkstra G, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Pierik MJ, van Kemenade FJ, de Kok IMCM, Siebers AG, Manniën J, van der Woude CJ, de Vries AC. Goetgebuer RL, et al. Among authors: ponsioen cij. J Crohns Colitis. 2021 Sep 25;15(9):1464-1473. doi: 10.1093/ecco-jcc/jjab036. J Crohns Colitis. 2021. PMID: 33609353 Free PMC article.
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M; Initiative on Crohn and Colitis. Straatmijer T, et al. Clin Gastroenterol Hepatol. 2023 Jan;21(1):182-191.e2. doi: 10.1016/j.cgh.2022.04.038. Epub 2022 May 26. Clin Gastroenterol Hepatol. 2023. PMID: 35644343 Free article.
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F, Maljaars J, Gecse K, Ponsioen C, Grootjans J, Hanzel J, Tack G, Jansen J, Hoentjen F, de Boer N, van der Marel S, Dijkstra G, Oldenburg B, Löwenberg M, van der Meulen A, D Haens G; IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis. Volkers A, et al. Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. doi: 10.1111/apt.17153. Epub 2022 Jul 23. Aliment Pharmacol Ther. 2022. PMID: 35869807 Free PMC article.
44 results